NCT06295692View on ClinicalTrials.gov

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 9, 2024

Primary Completion Date

April 15, 2025

Study Completion Date

October 14, 2027

Conditions
Generalized Pustular PsoriasisErythrodermic Psoriasis
Interventions
DRUG

JNJ-77242113

JNJ-77242113 tablet will be administered orally.

Trial Locations (12)

060-0033

JR Sapporo Hospital, Hokkaido

491-8558

Ichinomiya Municipal Hospital, Ichinomiya

173 8606

Teikyo University Hospital, Itabashi Ku

807-8556

Hospital of the University of Occupational and Enviromental Health, Kitakyushu-shi

860-8556

Kumamoto University Hospital, Kumamoto

467 8602

Nagoya City University Hospital, Nagoya

550 0006

Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital, Osaka

980 8574

Tohoku University Hospital, Sendai

321 0293

Dokkyo Medical University Hospital, Shimotsuga Gun

160 0023

Tokyo Medical University Hospital, Shinjuku

470-1192

Fujita Health University Hospital, Toyoake

514 8507

Mie University Hospital, Tsu

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT06295692 - A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | Biotech Hunter | Biotech Hunter